International Dermatology Outcome Measures (IDEOM) – Report from the 2022 Annual Meeting
December 2023 | Volume 22 | Issue 12 | 1153 | Copyright © December 2023
Published online November 16, 2023
Kathryn Lee BAa*, Michael J. Woodbury BSb*, Melissa Peri Zundell BSc, Rosario Aguero MDd, Jenna Yousif BSc, Samuel Clay Williams BAe, David Rosmarin MD FAADf, Nanette Silverberg MDc, Diane Thiboutot MDg, Cecilia Larocca MDh, Michi M. Shinohara MDi, Arash Mostaghimi MD MPA MPHb, Sonja Stander MDj, Antonio Martorell MD PhDk, Tarannum Jaleel MDl, Richard L. Torbeck MDc,m, Daniel M. Siegel MD MA FAADn,o, Lourdes Perez-Chada MD MMSc,p, Vibeke Strand MDq, April W. Armstrong MD MPHr**, Joseph F. Merola MD MMSc,s**, Alice B. Gottlieb MD PhDc**
aSaint Louis University School of Medicine, St. Louis, MO
bDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
cDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
dDepartment of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA
eWeill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD program, New York, NY
fDepartment of Dermatology, Indiana School of Medicine, Indianapolis, IN
gDepartment of Dermatology, Pennsylvania State University, PennState Health, Hershey, PA
hDepartment of Dermatology, Harvard Medical School, Brigham and Women's Hospital & Dana-Farber Cancer Institute, Boston, MA
iDivision of Dermatology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA
jDepartment of Dermatology and Center for Chronic Pruritus, University Hospital Munster, Munster, Germany
kDepartment of Dermatology, Hospital of Manises, Valencia, Spain
lDepartment of Dermatology, Duke University School of Medicine, Durham, NC
mDermatology Associates, Portland, ME
nDepartment of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY
oDepartment of Dermatology, VA New York Harbor Healthcare System, Brooklyn, NY
pDepartment of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
qDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
rDivision of Dermatology, University of California Los Angeles, Los Angeles, CA
sDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
*Co-first authors, **Co-senior authors
Abstract
Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures in dermatological diseases. Researchers and stakeholders from various backgrounds collaborate to develop these objective benchmark metrics to further advance treatment and management of dermatological conditions.
Summary: The 2022 IDEOM Annual Meeting was held on June 17-18, 2022. Leaders and stakeholders from the hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, cutaneous lymphoma, and psoriatic disease workgroups discussed the progress of their respective outcome-measures research. This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting.
J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615
INTRODUCTION
International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. IDEOM's mission is to establish patient-centered outcome measures within dermatology through consensus-driven efforts.1 Such outcome measures greatly benefit healthcare providers and researchers in determining patient progress and appropriate treatments in addition to healthcare payers in determining optimal payment policies. Therefore, IDEOM offers a unique opportunity for key patient, physician, industry, government, and insurer stakeholders to contribute to the establishment of such outcome measures.
To best achieve IDEOM's mission, IDEOM has created workgroups dedicated to a number of dermatologic conditions. The workgroups are composed of key stakeholders in psoriasis, psoriatic arthritis (PsA), hidradenitis suppurativa (HS), acne, vitiligo, actinic keratosis (AK), alopecia areata (AA), itch, and cutaneous lymphoma. The methodology followed by the workgroups is informed by evidence-based resources published by Outcome Measures in Rheumatology (OMERACT), Core Outcomes Measures in Effectiveness Trials (COMET), and COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN) initiatives.2,3 These
